羅欣藥業(002793.SZ):布洛芬注射用濃溶液獲得藥品註冊證書
格隆匯5月27日丨羅欣藥業(002793.SZ)公佈,近日,羅欣藥業集團股份有限公司下屬子公司山東羅欣藥業集團股份有限公司收到國家藥品監督管理局覈準簽發的布洛芬注射用濃溶液《藥品註冊證書》。
布洛芬屬非甾體類抗炎藥,具有鎮痛、抗炎、解熱作用,是一種有效的前列腺素(PG)合成抑制劑。病原體及其毒素侵襲人體後,產生與釋放內熱原,使中樞合成並釋放PG增多,PG是一類具有高度生物活性的物質,參與機體發熱、疼痛、炎症、血栓形成、過敏等多種生理、病理過程,非甾體類抗炎藥能抑制合成前列腺素所必須的環加氧酶(COX)的活性,從而阻止PG的合成來發揮其藥理作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.